Overall rank by patents
#24,742
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).
The verdict
Medicomp holds 11 US patents across 5 technology areas, rank #24,742 of 50,000 tracked assignees.
Medicomp Systems, Inc. has been granted 11 US utility patents between 2016 and 2025, placing Medicomp Systems, Inc. at rank #24,742 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.3 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, Medicomp Systems, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Medicomp sits between MCCI Corporation (11 patents, rank #24,738) and MEP Tech, Inc. (11 patents, rank #24,746) - the closest US assignees by grant volume. The composite Innovation Score of 36.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Medicomp Systems, Inc.'s 15.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Medicomp Systems, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
MCCI Corporation
11 patents
MCE 5 Development
11 patents
MCKEON ROLLING STEEL DOOR CO., INC.
11 patents
MEDEON BIODESIGN, INC.
11 patents
MEDIMPACT HEALTHCARE SYSTEMS, INC.
11 patents
MEGGITT AEROSPACE LIMITED
11 patents
MELITTA EUROPA GMBH & CO. KG
11 patents
MEP Tech, Inc.
11 patents
MEDICOMP SYSTEMS, INC.
11 patents
What this shows Medicomp holds 11 patents at rank #24,742, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Medicomp's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
37 Top 45% higher than 55% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 9.1% |
| 2018 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2020 | 1 | 9.1% |
| 2022 | 1 | 9.1% |
| 2023 | 3 | 27.3% |
| 2024 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Top 5 of 5 technology areas
Overall rank by patents
#24,742
Across all tracked assignees
36.8 out of 100
How to use this portfolio
Medicomp's 11 grants land it in the top 45% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.